SCHEMBL16487173

SCHEMBL16487173

COC(=O)c1ccc(=O)n(Cc2ccc(Cn3ccccc3=O)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.58
KDM4E B2RXH2 1/20 0.58
BRD4 O60885 1/20 0.56
BRD2 P25440 1/20 0.56
BRD3 Q15059 1/20 0.56
BRDT Q58F21 1/20 0.56
LMNA P02545 2/20 0.54
KLKB1 P03952 6/20 0.51
KLK1 P06870 2/20 0.51
ALDH1A1 P00352 3/20 0.50
MAPK10 P53779 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
POLB P06746 1/20 0.46
IDH1 O75874 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11316074 0.89 BRD4 (0.70) GAAKDM4EBRD4BRD2BRD3
SCHEMBL16880667 0.88 KLKB1 (0.51) GAAKDM4EBRD4BRD2BRD3
SCHEMBL7233513 0.87 BRD4 (0.60) GAAKDM4EBRD4BRD2BRD3
SCHEMBL16891582 0.87 KLKB1 (0.50) GAAKDM4EBRD4BRD2BRD3
SCHEMBL16881507 0.85 KDM4E (0.54) GAAKDM4EBRD4BRD2BRD3
SCHEMBL17818633 0.85 GAA (0.59) GAAKDM4EBRD4BRD2BRD3
SCHEMBL15033057 0.85 GAA (0.59) GAAKDM4EBRD4BRD2BRD3
SCHEMBL2463599 0.84 KDM4E (0.57) GAAKDM4EBRD4BRD2BRD3
SCHEMBL16486417 0.83 BRD4 (0.58) GAAKDM4EBRD4BRD2BRD3
SCHEMBL29779638 0.82 BRD4 (0.53) GAABRD4BRD2BRD3BRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153724-A1 Inhibitors Of Plasma Kallikrein KALVISTA PHARMACEUTICALS LTD (GB) 2022-05-19 US disclosed
US-11242333-B2 Inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-08 US disclosed
US-20190152950-A1 Inhibitors Of Plasma Kallikrein KALVISTA PHARMACEUTICALS LTD (GB) 2019-05-23 US disclosed
US-10221161-B2 Inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LIMITED (GB) 2019-03-05 US disclosed
EP-3033336-B1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2018-05-30 EP disclosed
EP-3033336-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2016-06-22 EP disclosed
US-20160168123-A1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-06-16 US disclosed
WO-2015022546-A1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LIMITED (GB) 2015-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152950-A1 Inhibitors Of Plasma Kallikrein KLKB1, SERPINB1, KLK5 GAA 722/4885KDM4E 1741/4885BRD4 2515/4885
US-20220153724-A1 Inhibitors Of Plasma Kallikrein KLKB1, SERPINB1, KLK5 GAA 722/4885KDM4E 1741/4885BRD4 2515/4885
US-11242333-B2 Inhibitors of plasma kallikrein KLKB1, SERPINB1, KLK5 GAA 722/4885KDM4E 1741/4885BRD4 2515/4885
US-10221161-B2 Inhibitors of plasma kallikrein KLKB1, SERPINB1, KLK5 GAA 722/4885KDM4E 1741/4885BRD4 2515/4885
US-20160168123-A1 INHIBITORS OF PLASMA KALLIKREIN KLKB1, SERPINB1, KLK5 GAA 722/4885KDM4E 1741/4885BRD4 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.